132 completed, 19 unknown, 15 terminated, 10 recruiting. 65 Phase 2, 44 Phase 3, 39 Phase 4, 27 Phase 1, 16 Not applicable.
Follow Allopurinol: new trials by email Literature Review of Allopurinol trials Research Report on Allopurinol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allopurinol in Depression Sertraline 50 MG, Allopurinol 300 MG - Depression | Phase 2 / Phase 3 | Recruiting | Tanta University | 70 | 2026-05-20 | 2026-08-18 |
| Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia Febuxostat, allopurinol - Hyperuricemia, Renal Insufficiency, Chronic | Not applicable | Active not recruiting | Nishtar Medical University | 66 | 2026-05-13 | 2026-09-30 |
| Drug-Drug Interaction Study of ABP-671 in Gout Patients ABP-671 plus allopurinol - Gout Chronic, Gout | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 22 | 2026-01-23 | 2026-11-02 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver Allopurinol Tablet, Placebo - Cirrhoses, Liver, Decompensated Cirrhosis of Liver | Phase 4 | Recruiting | Bangladesh Medical University | 54 | 2025-09-10 | 2026-09-02 |
| A Study of Dotinurad Versus Allopurinol in Tophaceous Gout Allopurinol, Dotinurad - Tophaceous Gout | Phase 3 | Recruiting | Crystalys Therapeutics | 250 | 2025-08-04 | 2026-11-12 |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout Allopurinol, Dotinurad - Gout | Phase 3 | Recruiting | Crystalys Therapeutics | 500 | 2025-08-01 | 2026-11-12 |
| Allopurinol Improves Heart Function in African Americans With Resistant Hypertension Allopurinol - Heart Failure Preserved Ejection Fraction, Resistant Hypertension | Phase 2 | Completed | VA Office of Research and Development | 40 | 2024-09-30 | 2026-09-04 |
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg - Gout | Phase 4 | Recruiting | Massachusetts General Hospital | 650 | 2024-02-22 | 2026-11-18 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk Allopurinol 200 mg, Optional intervention - Cardiovascular Diseases, Uric Acid | Phase 3 | Recruiting | Poznan University of Medical Sciences | 1116 | 2023-09-01 | 2025-01-06 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout ABP-671, Allopurinol, Placebo - Gout | Phase 2 / Phase 3 | Completed | Atom Therapeutics Co., Ltd | 300 | 2023-08-11 | 2025-12-22 |
| ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS Allopurinol - Diabetic Kidney Disease (DKD) | Not applicable | Completed | Narowal Medical College | 80 | 2023-05-14 | 2025-09-17 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout D-0120, Allopurinol - Gout | Phase 2 | Completed | InventisBio Co., Ltd | 80 | 2023-04-17 | 2026-07-09 |
| Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 2202 | 2023-03-30 | 2025-07-22 |
| Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) Mycophenolate Mofetil, Allopurinol, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1 | Terminated | Washington University School of Medicine | 17 | 2023-02-27 | 2024-12-05 |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) Pirtobrutinib, Obinutuzumab, Venetoclax - Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2022-12-20 | 2026-04-30 |
| Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients Trimetazidine 35 mg, Allopurinol 300 MG, Normal saline - AKI - Acute Kidney Injury | Phase 4 | Unknown | Beni-Suef University | 124 | 2022-09-19 | 2023-01-19 |
Showing 20 of 183. Sign in to see all of them.
Gout (45) · Hyperuricemia (35) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Renal Insufficiency, Chronic (11) · Cardiovascular Diseases (10) · Leukemia (10) · Leukemia, Myeloid, Acute (8) · Lymphoma (8) · Lymphoma, Non-Hodgkin (8) · Burkitt Lymphoma (7) · Heart Failure (7) · Hypertension (7) · Myelodysplastic Syndromes (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Follicular (5)
Ardea Biosciences, Inc. (10) · AstraZeneca (7) · Masonic Cancer Center, University of Minnesota (6) · Takeda (6) · Tanta University (5) · University of Dundee (5) · Alliance for Clinical Trials in Oncology (4) · Arthrosi Therapeutics (3) · Atom Therapeutics Co., Ltd (3) · Gilead Sciences (3) · Instituto Nacional de Cardiologia Ignacio Chavez (3) · M.D. Anderson Cancer Center (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · The University of Texas at Arlington (3)
United States (93) · United Kingdom (13) · Canada (11) · Germany (11) · Poland (11) · Spain (11) · Australia (8) · Egypt (8) · China (7) · Italy (6) · Mexico (6) · Taiwan (6) · Belgium (5) · Brazil (5) · Georgia (5)
N. Bhakta (3) · Allan Struthers, MD FRCP (2) · Chris Storgard, MD (2) · Daniel I Feig, MD, PhD (2) · Magdalena Madero, MD (2) · AA Levine (1) · Adrian Hernandez, MD (1) · Ahmed A. Shokeir, MD (1) · Alaattin Yildiz, Prof, MD (1)
PMID 21849262, PMID 21353107, PMID 22052584, PMID 35835008, PMID 18600509, PMID 37832758, PMID 12421831, PMID 15698861, PMID 16339094, PMID 17241381, PMID 18349746, PMID 18681754, PMID 18728266, PMID 18975369, PMID 19286847, PMID 19564319, PMID 20029377, PMID 20370912, PMID 20674758, PMID 20952687, PMID 22132950, PMID 22316106, PMID 22361399, PMID 22420596, PMID 22436129, PMID 22483162, PMID 22795277, PMID 23006736, PMID 23098865, PMID 23395281, PMID 23683134, PMID 23740194, PMID 23929928, PMID 24352085, PMID 24428673, PMID 24530972, PMID 25512466, PMID 25986447, PMID 26013187, PMID 26190562, PMID 26216382, PMID 26277090, PMID 26724837, PMID 26742777, PMID 26989892, PMID 27564409, PMID 27821644, PMID 28739782, PMID 29527974, PMID 29531784
U10CA031946 (4), 2017 (3), 2014 (2), 2016 (2), K23DK064587 (2), 2018 (1), 2019 (1), I21RX004655 (1), K23DK088833 (1), K23HL071562 (1), P30CA016056 (1), P50AR060772 (1), R01DK103729 (1), R01HL061912 (1), R01HL079352 (1)